Tezepelumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tezepelumab and local guidelines before prescribing.
Biologic (anti-TSLP)
Mechanism
Anti-TSLP monoclonal antibody.
Uses
Severe asthma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Pharyngitis, arthralgia, injection-site reactions.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active parasitic infection
Monitoring
Asthma control
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Works regardless of eosinophil count.
More from the textbook: uses, cautions and other points
- Tezepelumab | TSLP (an "upstream" alarmin) | Severe asthma including non-eosinophilic types
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab / mepolizumab / benralizumab / dupilumab / tezepelumab | Biologics for severe asthma (specialist).
Respiratory: Anatomy, Physiology and Pharmacology - Tezepelumab (anti-TSLP): Acts "upstream" and works in both eosinophilic and non-eosinophilic severe asthma.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - TSLP | Tezepelumab | Severe asthma (all phenotypes) | Well tolerated
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (2 mentions)
- Respiratory: Airways Disease (2 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (2 mentions)